December 20, 2021

Eli Lilly and Company

Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A.
+1.317.276.2000
www.lilly.com

Lilly's statement on its monoclonal antibody therapies neutralization activity against the Omicron variant of concern

Lilly has completed analysis of its antibody therapies, including bamlanivimab with etesevimab, along with our investigational antibody bebtelovimab, against the Omicron variant of concern. As expected, we have confirmed reduced neutralization activity of bamlanivimab with etesevimab against the Omicron variant of concern.

We can also report that our investigational antibody, bebtelovimab, maintains neutralization activity against all known variants of concern, including Omicron.

It has always been our view that additional monoclonal antibodies may be needed to address the evolution of the virus. In fact, this is what drove our work on bamlanivimab and etesevimab together, and to begin development of bebtelovimab in January 2021.

Lilly's role in fighting the COVID-19 pandemic has been driven by our purpose – to create medicines that make life better – and our therapies have helped to save tens of thousands of lives.

We are encouraged that the next generation of treatments – such as oral antivirals – may soon be available as these can be manufactured and administered more efficiently. Lilly is talking with regulators to understand the potential need for additional therapies, like bebtelovimab, and will continue to do our part based on the available science and needs of society.